EMEA-001115-PIP01-10-M07

Key facts

Invented name
Adasuve
Active substance
loxapine
Therapeutic area
Psychiatry
Decision number
P/0385/2019
PIP number
EMEA-001115-PIP01-10-M07
Pharmaceutical form(s)
Inhalation powder, pre-dispensed
Condition(s) / indication(s)
  • Treatment of bipolar disorder
  • Treatment of schizophrenia
Route(s) of administration
Inhalation use
Contact for public enquiries
Ferrer Internacional S.A.

E-mail: lmoya@ferrer.com, agrima@ferrer.com, smartin@ferrer.com
Tel.  +34 935093248, +34 935093242, +34 935082981

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating